Protective effects of gonadotropin releasing hormone agonist on ovarian function in patients with early stage cervical cancer undergoing ovarian preservation
10.3969/j.issn.1005-1678.2017.06.015
- VernacularTitle:促性腺激素释放激素激动剂对早期宫颈癌行保留卵巢根治术患者卵巢功能的保护作用
- Author:
Kemiao ZHU
;
Xiaoping CHEN
;
Yuling FU
- Keywords:
gonadotropin releasing hormone agonist;
early stage cervical cancer;
ovarian radical operation;
ovarian function
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(6):48-50
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the protective effect of gonadotropin releasing hormone agonist on ovarian function in patients with early stage cervical cancer.Methods80 cases ofadmitted patients with early stage cervical cancerfrom January 2015 to January 2016 in Yinzhou Second Hospital were selected, were randomly divided to observation group and control group.Patients in the observation group were retained ovarian resection, while giving the gonadotropin releasing hormone (GnRH) agonist treatment, the control group patients only with reservation of ovary resection and compared between the two groups before and after chemotherapy in patients with basal follicle stimulation hormone (bFSH) levels, serum anti Mullerian tube hormone (AMH) level, basic estrogen (bE2) levels, and the basal antral follicle number (bafc).ResultsThere were no significant differences in two groups of chemotherapy in patients with anterior bFSH and bE2 level, after chemotherapy, the observation group patients bFSH and bE2 level was significantly lower than that in control group (P<0.05) and chemotherapy after bFSH level of two groups of patients were higher than that in the chemotherapy before.bE2 levels were lower than those before chemotherapy (P<0.05);chemotherapy the number of patients in the two groups of AMH level and bafc without significant difference, after chemotherapy, the observation group AMH levels and bafc number were significantly higher than those of the control group (P<0.05) and chemotherapy after two groups of patients with AMH levels and bafc number lower than the chemotherapy before (P<0.05).ConclusionGnRH agonists can effectively protect the early cervical cancer patients with radical resection of ovarian reserve and ovarian reserve function, clinical application is worthy of further promotion.
